Efficacy and Safety of Aficamten in Symptomatic Non-Obstructive Hypertrophic Cardiomyopathy: Results From the REDWOOD-HCM Trial, Cohort 4

Association Between Beta Blocker Use and Incidence of New Atrial Fibrillation and Flutter Post-Septal Myectomy for Obstructive Hypertrophic Cardiomyopathy

Standard of Care Medication Patterns of Use Before and After Septal Myectomy in Patients with Obstructive Hypertrophic Cardiomyopathy

Racial and Ethnic Differences in Cardiovascular Outcomes in Patients Diagnosed with Hypertrophic Cardiomyopathy

Efficacy and Safety of Aficamten in the First Cohort of Patients With Symptomatic Obstructive Hypertrophic Cardiomyopathy Completing 48-Week Follow-up: Findings From FOREST-HCM

Effect of Moderate Hepatic Impairment on the Pharmacokinetics of Aficamten and its Metabolites

Drug–Drug Interaction Study to Evaluate the Effect of Strong CYP3A Inhibition and P450 Induction on the Pharmacokinetics of Aficamten and the Effect of Aficamten on P-Glycoprotein in Healthy Participants

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single and Multiple Doses of Aficamten in Healthy Chinese Participants: a Randomized, Double-Blind, Placebo-Controlled, Phase 1 Study

Aficamten for Drug-Refractory Severe Obstructive Hypertrophic Cardiomyopathy in Patients Receiving Disopyramide: REDWOOD-HCM Cohort 3

Potential Applicability of Omecamtiv Mecarbil to Patients Hospitalized for Worsening Heart Failure